TITAN PHARMACEUTICALS INC
TITAN PHARMACEUTICALS INC (TTNP): 1 pipeline candidate · ~13 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
12.7 months
D/E 0.09 · 0% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for TITAN PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$2.8M
Quarterly Burn
$680K
Runway
12.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| tp-2021 | Preclinical |
Frequently asked questions
How many drug candidates are in TITAN PHARMACEUTICALS INC's pipeline?
TITAN PHARMACEUTICALS INC (TTNP) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is TITAN PHARMACEUTICALS INC's lead drug candidate?
TITAN PHARMACEUTICALS INC's most advanced tracked candidate is tp-2021 (Preclinical) for chronic pruritus.
What is TITAN PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TITAN PHARMACEUTICALS INC has approximately 12.7 months of cash runway.
Who is the CEO of TITAN PHARMACEUTICALS INC?
Chay Weei Jye is the chief executive officer of TITAN PHARMACEUTICALS INC (TTNP).
Get the full picture on TITAN PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.